, and an anti-GPIIb/IIIa antibody inhibited NNKY5-5-induced SAF, but had no effect on 64-kD protein formation (SAF). Platelets in hirudin-anticoagulated plasma or washed platelets showed little response to NNKY5-5 tyrosine phosphorylation or p72 syk activations. Various inhibitors, including aspirin and protein kinase C, had no effect alone, but the antibody potentiated aggregation induced by low concentrations of adenosine diphosphate or plateleton SAF, protein tyrosine phosphorylation, or p72 syk activation. In contrast, tyrphostin 47, a potent tyrosine kinase inactivating factor. NNKY5-5 did not induce granule release or intracellular ing FcgRII itself, suggesting that such phosphorylation may be involved in this signaling pathway. 8 In addition, p72 syk sponses, including shape change, aggregation, and granule secretion. The process of signal transduction involves the shows noncovalent binding to the FcgRII on cross-linking of this receptor. 9 These observations suggest that activation breakdown of phospholipids, arachidonic acid metabolism, calcium mobilization, and the phosphorylation of specific of tyrosine kinases and tyrosine phosphorylation are involved in the early stage of platelet aggregation after the proteins, events mediated by the activation of various kinases.
, and an anti-GPIIb/IIIa antibody inhibited NNKY5-5-induced SAF, but had no effect on 64-kD protein formation (SAF). Platelets in hirudin-anticoagulated plasma or washed platelets showed little response to NNKY5-5 tyrosine phosphorylation or p72 syk activations. Various inhibitors, including aspirin and protein kinase C, had no effect alone, but the antibody potentiated aggregation induced by low concentrations of adenosine diphosphate or plateleton SAF, protein tyrosine phosphorylation, or p72 syk activation. In contrast, tyrphostin 47, a potent tyrosine kinase inactivating factor. NNKY5-5 did not induce granule release or intracellular Ca 2" mobilization. However, NNKY5-5 caused hibitor, inhibited NNKY5-5-induced SAF as well as tyrosine phosphorylation and p72 syk activation. Our findings suggest tyrosine phosphorylation of a 64-kD protein and activation of a tyrosine kinase, p72
syk . An anti-FcgII receptor antibody that binding of NNKY5-5 to GPIb potentiates platelet aggregation by facilitating the interaction between fibrinogen and had no effect on SAF, suggesting that NNKY5-5 activated platelets by interacting with glycoprotein Ib. Fab fragments GPIIb/IIIa through a mechanism associated with p72 syk activation and tyrosine phosphorylation of a 64-kD protein. LATELETS PROVIDE an excellent model for investigation of the mechanisms of signal transduction. Agonist-induced activation of platelets leads to a variety of reing FcgRII itself, suggesting that such phosphorylation may be involved in this signaling pathway. 8 In addition, p72 syk sponses, including shape change, aggregation, and granule secretion. The process of signal transduction involves the shows noncovalent binding to the FcgRII on cross-linking of this receptor. 9 These observations suggest that activation breakdown of phospholipids, arachidonic acid metabolism, calcium mobilization, and the phosphorylation of specific of tyrosine kinases and tyrosine phosphorylation are involved in the early stage of platelet aggregation after the proteins, events mediated by the activation of various kinases. 1 Recently, an increasing body of evidence has sugbinding of ligands to receptors on the platelet membrane. The GPIb complex is a heterodimer containing both GPIb gested that tyrosine phosphorylation of proteins plays an and GPIX. GPIb consists of disulfide-linked heavy (Ib a) important role in receptor-mediated transmembrane signaland light (Ib b) chains. GPIX and GPV show noncovalent ing during platelet activation. [2] [3] [4] In particular, tyrosine phosbinding to GPIb. 10, 11 Platelet adhesion to the subendothelium phorylation catalyzed by tyrosine kinases appears to influof damaged vessels is the initial hemostatic response to vasence platelet membrane glycoproteins. Recent studies have cular injury, and the interaction between von Willebrand shown that when glycoprotein (GP) IIb/IIIa is activated by factor (vWF) and GPIb is the primary event in this response. a specific monoclonal antibody (MoAb), tyrosine phosphoryGPIb also plays a key role in initiating platelet activation lation of certain proteins occurs 5 and the tyrosine kinase during shear-induced platelet aggregation. 12 Recent reports p72 syk is activated. 6 Several tyrosine kinases (fyn, lyn, and have provided evidence for the involvement of tyrosine yes) are physically associated with GPIV, and the interaction phosphorylation and tyrosine kinases in vWF and GPIbbetween GPIV and these kinases is believed to activate sigmediated platelet activation. 13, 14 Although the molecular naling pathways through tyrosine phosphorylation.
7 Platelet mechanism of the interaction between GPIb and vWF has been investigated extensively, the intracellular signal transduction pathway remains largely unknown. In the presence tion. 19 In the present study, we determined the effects of clear Blot Membrane P (Atto, Tokyo, Japan). The membranes were Tokyo, Japan) and Dr Makoto Handa (Keiou Medical University, incubated with 1% bovine serum albumin in phosphate-buffered Tokyo, Japan). saline, washed, and then incubated with PY-20, an MoAb specific Platelet preparation. Whole blood from healthy donors was colfor phosphotyrosine residues. Antibody binding was detected using lected into tubes containing 110 mmol/L trisodium citrate (1:9) or peroxidase-conjugated goat anti-mouse IgG and visualized with enhirudin and centrifuged at 200g for 10 minutes at room temperature hanced chemiluminescence detection reagents (Amersham Co, to obtained platelet-rich plasma (PRP). To obtain washed platelets, Buckinghamshire, UK). 1 mmol/L prostaglandin E 1 was added to PRP, and the mixture was Immunoprecipitation kinase assay. Platelets were incubated centrifuged at 800g for 15 minutes. Platelets were washed twice in with NNKY5-5, and incubation was terminated at the specified times a platelet-washing buffer (10 mmol/L Tris-HCl, 150 mmol/L NaCl, by addition of an equal volume of ice-cold lysis buffer (2% Triton 1 mmol/L EDTA, and 5 mmol/L glucose, pH 7.4), and were resus-X-100, 100 mmol/L Tris/HCl, pH 7.5, 50 mmol/L NaCl, 5 mmol/ pended in HEPES-Tyrode's buffer (138 mmol/L NaCl, 2.8 mmol/L L EDTA, 2 mmol/L vanadate, 1 mmol/L PMSF, and 100 mg/mL KCl, 1 mmol/L CaCl 2 , 0.5 mmol/L MgCl 2 , 0.5 mmol/L NaH 2 PO 4 , leupeptin). 25 Then the lysate was sonicated and centrifiged at 16,000g 12 mmol/L NaHCO 3 , 10 mmol/L glucose, and 10 mmol/L HEPES, for 5 minutes. The supernatant was precleared twice with sepharose pH 7.4). In some experiments, platelets were separated from plasma beads, mixed with anti-p72 syk or anti-p60 c-src antibody bound to proby gel filtration on a sepharose-2B column equilibrated with HEPEStein A sepharose or CNBr-activated sepharose, and stirred for 2 Tyrode's buffer. 20 hours at 4. Next, the sepharose beads were washed three times with NNKY5-5. NNKY5-5 (IgG2b), a MoAb directed against GPIb, lysis buffer and divided into two portions. One portion was used was produced by immunizing BALB/c mice as described predirectly for immunoblotting, as described below, and the other was viously. 19 An attempt was made to produce F(ab) 2 fragments of processed further for the in vitro kinase assay. 26 These beads were NNKY5-5 using pepsin digestion, 21 but only Fab fragments and the washed once with low-salt buffer (100 mmol/L NaCl, 5 mmol/L Fc portion were obtained. As described in a previous report, 21 mouse MnCl 2 , 10 mmol/L Tris [pH 7.4]), and were incubated with 25 mL IgG2b is generally degraded to Fab, but not F(ab) 2 by pepsin of kinase reaction buffer (20 mmol/L Tris, pH 7.5, 10 mmol/L digestion. We confirmed the Fab fragment of pepsin-digested MnCl 2 ) in the presence or absence of 10 mg of acid-treated enolase. NNKY5-5 by sodium dodecyl sulfate-polyacrylamide gel electroThe reaction was initiated by the addition of 10 mCi of [g-32 P] ATP phoresis (SDS-PAGE) with and/or without reduction by 2-mercaptoand 2 mmol/L ATP. After 10 minutes at 20, the reaction was stopped ethanol. Thus, the effects of the intact antibody and its Fab fragment, by the addition of Laemmli buffer and boiling for 3 minutes. For but not those of the F(ab) 2 fragment, were evaluated in this study.
immunoblotting, proteins were separated under reducing conditions Assessment of platelet aggregation and adenosine triphosphate by 8% or 12% SDS-PAGE and electrically transferred onto a Clear (ATP) production. PRP and washed platelets were adjusted to a Blot Membrane P (Atto). The membrane was treated with 1 mol/L final concentration of 3 1 10 8 /mL and preincubated with luciferin-KOH for 60 minutes, dried, and quantified with a BAS-2000 Phosluciferase. Platelet aggregation and ATP production were measured phor imager (Fuji Film, Tokyo, Japan). using a lumi-aggregometer (Payton, Scarborough, Canada). Various inhibitors were added to the PRP at 10 minutes before NNKY5-5, to determine their effects on aggregation induced by this MoAb. RESULTS 
Assessment of platelet aggregation by light scatter. Platelet ag-

Characterization of NNKY5-5.
A previous study 19 gregation was also measured by the particle counting technique using showed that NNKY5-5 is an IgG2b antibody. There was light scatter. 22 Briefly, a diode laser light beam (width: 40 mm; wavelength: 675 nm) was passed through PRP in a cylindrical glass very little binding of NNKY5-5 to Bernard Soulier syndrome AID Blood 0020 / 5h2f$$$381 01-29-97 00:54:39 blda WBS: Blood NNKY5-5 (10 mg/mL) induced irreversible aggregation of citrate-anticoagulated PRP, with the change in light transmission ranging from 10% to 15%. The aggregation curve showed a gentle slope, a minimal lag time, and no fluctuation ( Fig 1C) . We defined this phenomenon as SAF. Although the extent of the change in light transmission differed slightly among individuals, all the platelet samples obtained from 10 healthy donors responded to NNKY5-5. A wide variety of antiplatelet MoAbs induce platelet aggregation, with the majority activating platelets through FcgRII-dependent mechanisms. 28 Therefore, we evaluated the effect of IV.3, an antiFcgRII MoAb, on SAF induced by NNKY5-5 as well as the effect of pepsin-digested fragments of NNKY5-5 that did not include the Fc portion. IV.3 failed to inhibit SAF induced by NNKY5-5 (Fig 1D) . We were not able to obtain F(ab) 2 fragments of NNKY5-5, but Fab fragments caused no detectable SAF (Fig 1E) . Use of a secondary antibody to crosslink the receptor-bound NNKY5-5 Fab also induced SAF (Fig 1F) . These findings suggested that NNKY5-5-induced SAF was independent of FcgRII activation and that divalent binding of the antibody was required. The other anti-GPIb MoAbs (TM-60, 29 SZ-2, 30 and WGA-III) did not induce any platelet aggregation (data not shown).
Assessment of platelet aggregation by light scatter. Since NNKY5-5 induced only slight changes in light transmission, it was possible that this MoAb induced shape change but not aggregation. Therefore, aggregation was also assessed by a newly developed light scatter method, which could detect the formation of small aggregates as well as large ones and allowed quantification of the number and size 6 to 100 platelets in a time-dependent manner (Fig 2A) . IIIa and fibrinogen, as well as NNKY1-32 (10 mg/mL), an anti-GPIIb/IIIa MoAb, which interferes with fibrinogen binding, 31 potently inhibited NNKY5-5-induced SAF (Fig  platelets. The molecular weight of the platelet-membrane 2B). When blood samples were anticoagulated with 50 U/ antigen recognized by NNKY5-5 was determined to be 150 mL hirudin instead of citrate, ADP-induced platelet aggregakD under reducing conditions. We also analyzed the amino tion was similar to that obtained with citrate-anticoagulated acid sequence of the NNKY5-5-immunoprecipitated protein samples. In contrast, the aggregation induced by NNKY5-5 by microsequencing. Glycocalicine was applied to NNKY5-was greatly reduced (Fig 2C) . In addition, washed platelets 5-immobilized Sepharose and protein was eluted with 2 only showed a minimal response to NNKY5-5 (data not mol/L guanidine HCl in 0.1 mol/L sodium acetate buffer shown). (pH 4.0)/1.5 mol/L NaCl. After dialysis, the eluted protein Potentiation of platelet aggregation induced by other agowas immobilized on a polyvinylidene difluoride (PVDF)
nists. The reduced or absent ability of NNKY5-5 to elicit membrane (ProSpin; Applied Biosystems Inc, Foster City, platelet aggregation in the presence of a physiological con-CA). Then the membrane was pyridylethylated and directly centration of Ca 2/ was reminiscent of the effects of epinephapplied to an amino acid sequence analyzer (model 473A, rine, which is not an aggregating agent in its own right but Applied Biosystems Inc). The sequence obtained was NH 2 -potentiates platelet aggregation induced by other agonists.
32
H-P-I-C-E-V-S-K-V-A, which corresponded to the reported Therefore, we evaluated the effect of NNKY5-5 on platelet N-terminal sequence of GPIb, 27 confirming the binding of aggregation induced by low concentrations of ADP or plate-NNKY5-5 to this glycoprotein. As shown in Fig 1A and let-activating factor (PAF). When platelets were activated B, NNKY5-5 completely inhibited ristocetin (1.5 mg/mL)-with 0.5 mmol/L ADP or 10 nmol/L PAF, there was transient induced platelet agglutination, but had no effect on collagenformation of small aggregates consisting of less than 100 or thrombin-induced aggregation. ]i, as assessed using fura 2-loaded platelets (data not shown). Resting platelets contain a major 60-kD protein band that shows heavy tyrosine phosphorylation and this protein is considered to be p60 c-src . 33 NNKY5-5 induced tyrosine phosphorylation of a 64-kD protein in a concentration-dependent manner. This band could be detected as early as 1 minute after the addition of NNKY5-5, and its density increased in a timedependent manner (Fig 4) . Addition of various inhibitors at 10 minutes before NNKY5-5 was also evaluated with respect to the effect on platelet aggregation and tyrosine phosphorylation of the 64-kD protein. Platelet aggregation was measured with PRP, because it was difficult to quantitate aggregate formation using washed platelets. However, tyrosine phosphorylation of the 64-kD protein was evaluated using washed platelets, because the presence of serum proteins circumvented the detections of platelet tyrosine phosphorylations. Aspirin or H-7, a protein kinase C inhibitor, failed to inhibit tyrosine phosphorylation of the 64-kD protein and platelet aggregation. GRGDS (a peptide that inhibits the binding of fibrinogen to GPIIb/IIIa) and EGTA (a chelator of extracellular Ca 2/ ) inhibited aggregation induced by NNKY5-5, but had no effect on phosphorylation of the 64-kD protein. Prostaglandin I 2 , a stimulator of adenylate cyclase, inhibited both NNKY5-5-induced protein phosphorylation and platelet aggregation. In the presence of tyrphostin 47 or herbimycin, which are potent tyrosine kinase inhibitors, 34, 35 no protein phosphorylation or platelet aggregation was observed. Table 1 summarizes the results obtained with various inhibitors. These findings suggested that NNKY5-5 induced phosphorylation of the 64-kD protein independent of thromboxane A 2 , protein kinase C, or platelet aggregation, but that tyrosine kinase activation (which was susceptible to p72 syk was rapidly activated by optimal concentrations of thrombin, with its activity increasing approximately 10-fold. p60 c-src is known to be activated with a slower time course mary aggregation, Fig 3B and D) . When platelets were preinand lower magnitude. 26 p60 c-src showed no change of activity cubated with 10 mg/mL NNKY5-5 for 2 minutes, the number in response to NNKY5-5 (data not shown). In contrast, of aggregates increased and the aggregates persisted for up NNKY5-5 increased the autophosphorylation of p72 syk from to 10 minutes after stimulation with ADP or PAF (Fig 3C  15 seconds after stimulation (Fig 5A) . This increase of p72 which showed a rapid increase in enzyme activity (Fig 5B) .
leading to the suggestion that GPIb also acts as a receptor In contrast to thrombin activation, the increase of p72 syk acfor collagen and thrombin. In the present study, we showed tivity induced by NNKY5-5 was of a lower magnitude, being that NNKY5-5, an anti-GPIb MoAb, not only completely 2.2-fold to fivefold. The band just above IgG has not been inhibited ristocetin-induced agglutination but also induced identified, but may be a protein that associates with p72 syk the formation of small aggregates in citrate anticoagulated after platelet activation induced by NNKY5-5. Activation of PRP. We used the term SAF for this formation of small p72 syk by NNKY5-5 was found to be independent of the aggregates, since it is currently unclear whether this phenomextracellular Ca 2/ concentration or platelet aggregation. enon is the same as ordinary platelet aggregation. To our p72 syk activation was also caused by Fab fragments of knowledge, this is the first report of an anti-GPIb MoAb NNKY5-5 (Fig 6) .
with platelet-activating properties. For example, Kelton and Horsewood 39 observed no activation when platelets were DISCUSSION stimulated with various MoAbs directed against the GPIb-IX complex. We also evaluated the effects of three other A number of MoAbs directed against GPIb inhibit ristoanti-GPIb MoAbs, and found that none of them had an action cetin-dependent binding of vWF to platelets and ristocetinsimilar to NNKY5-5. induced platelet agglutination, 29, 30, 37 confirming that vWF in-SAF was slight, amounting to a 10% to 15% change in teracts with GPIb. Some of these antibodies also inhibit collagen-induced 30,37 or thrombin-induced 38 aggregation, light transmission at most. A new platelet aggregometry, granules. 41, 42 These characteristics are quite similar to those
Inhibition was judged to be negative when its magnitude was less of NNKY5-5-induced platelet activation, suggesting that than 30% on densitometry. PGI2, tyrphostin, and herbmycin all caused they share a common mechanism of platelet activation. To almost complete inhibition of protein phosphorylation.
further characterize the mechanism, the effects of various 0, inhibited; /, not inhibited.
inhibitors were assessed on platelet aggregation and tyrosine based on particle counting using light scatter, showed that SAF consisted of small aggregates formed by less than 100 cells. No SAF was observed when platelets were treated with prostaglandin I 2 , suggesting that the platelet response to NNKY5-5 represented aggregation and not agglutination. However, SAF was greatly reduced when hirudin was used as the anticoagulant instead of citrate, suggesting that NNKY5-5 could not elicit this response in the presence of physiological levels of Ca 2/
. Washed platelets also showed a minimal response to NNKY5-5. Thus, NNKY5-5-induced SAF resembled that induced by epinephrine in several respects. Epinephrine is considered to be a potentiator of platelet activation but not a true aggregating agent, since it does not produce aggregation in the presence of a physiological concentration of Ca 2/ . 32 At low extracellular Ca 2/ concentrations, however, platelets become hypersensitive to epinephrine and form aggregates through a presently unidentified mechanism. Thus, we assessed whether NNKY5-5 acted as a potentiator of platelet aggregation induced by other agonists. NNKY5-5 increased the number of aggregates and the duration of aggregation induced by low concentrations of ADP, PAF, and U-46619 (a thromboxane A 2 agonist), suggesting for the potentiating effect of NNKY5-5.
The majority of antiplatelet antibodies that cause platelet activation are FcgRII-dependent. However, IV.3, an antiFcgRII MoAb that inhibits Fc receptor-dependent platelet activation, had no effect on SAF induced by NNKY5-5, suggesting that NNKY5-5 induced platelet activation is independent of FcgRII. We were not able to produce F(ab) 2 fragments of NNKY5-5, probably because it is an IgG2b antibody. Although the Fab fragment of NNKY5-5 failed to induce SAF, it potentiated platelet aggregation induced phosphorylation of the 64-kD protein induced by NNKY5-
In the present study, we found that NNKY5-5 induced platelet aggregates of small size in citrated-PRP. In the pres-5. Aspirin and H-7 had no inhibitory effect on aggregation and protein phosphorylation induced by NNKY5-5, sugence of vWF, botrocetin at concentrations below 0.5 mg/mL also induced the formation of small aggregates (data not gesting that platelet activation was independent of both the cyclooxygenase pathway and protein kinase C activation.
shown) similar to those induced by NNKY5-5. The persistent formation of small aggregates is not unique to platelet activa-GRGDS (a peptide which blocks fibrinogen binding to GPIIb/IIIa) at a concentration of 400 mmol/L and EGTA tion mediated by GPIb, since it is also observed with epinephrine-induced aggregation in the presence of inhibitors at 1 mmol/L inhibited NNKY5-5-induced SAF, although phosphorylation of the 64-kD protein was still observed, of thromboxane A2 production or cGMP-elevating agents. 45 However, unlike epinephrine, NNKY5-5 did not promote suggesting that it was not a consequence of the binding of fibrinogen to GPIIb/IIIa. In contrast, tyrphostin and herbithe formation of large platelet aggregates. Several factors appear to influence MoAb-mediated platelet activation, such mycin (protein tyrosine kinase inhibitors) potently suppressed both phosphorylation of the 64-kD protein and platethe number and density of the platelet epitopes and the affinity of the antibody for its epitope. 46-50 The mobility of glycolet aggregation. Taken together, these findings suggest that the binding of NNKY5-5 to GPIb induced tyrosine phosproteins within the platelet membrane 51 is also believed to be important. There are about 25,000 copies of GPIb-IX phorylation of the 64-kD protein catalyzed by a tyrosine kinase, and that the phosphorylated protein promoted the per platelet. 39 However, GPIb binds to a submembranous cytoskeleton composed of short actin filaments and actinactivation of GPIIb/IIIa with resultant SAF.
There is increasing evidence for an important role of tyrobinding protein, 52 which may reduces its mobility, and poor mobility of GPIb-IX may have contributed to the weak actisine kinases in the regulation of platelet function. 43 Although it is not yet clear which tyrosine kinase is responsible for vation induced by NNKY5-5 in the present study. GRGDS and NNKY1-32, an anti-GPIIb/IIIa MoAb which phosphorylating particular proteins, three of these kinases (p72 syk , p60
c-src
, and p125 FAK ) show a change in activity with potently blocks the interaction between GPIIb/IIIa and fibrinogen, 31 inhibited SAF induced by NNKY5-5, suggesting platelet stimulation. The activity of p72 syk rapidly increases by 10-fold with thrombin activation of platelets, reaching a that activation of GPIIb/IIIa plays an essential role in this process. Taken together, these findings suggest that the bindmaximum at 10 seconds. 36 Platelet activation also elevates p60 c-src activity, albeit to a lesser extent and with a slower ing of NNKY5-5 to GPIb initiates intracellular signals that activate GPIIb/IIIa. There is increasing evidence that activatime course. 35 In contrast, p125 FAK is only activated after the interaction between GPIIb/IIIa and fibrinogen has occurred. 44 tion of GPIb is linked to GPIIb/IIIa activation and subsequent fibrinogen binding. For example, the interaction of asialo These findings suggest that tyrosine kinases are actively engaged in the regulation of platelet function from the initial vWF with GPIb induces the binding of fibrinogen to GPIIb/ IIIa. 53 Bothrombin (purified from snake venom) interacts phase of activation to the late stage of aggregation. In the present study, we found that NNKY5-5 elicited a rapid inwith GPIb but not with the thrombin receptor, and induces platelet aggregation by activating GPIIb/IIIa. 54 Similar to crease in the activity of p72 syk but not p60 syk activation is involved in these prothe 64-kD protein because it is only activated after platelet aggregation. The Fab fragment of NNKY5-5, which itself cesses, as with NNKY5-5-induced platelet activation, remains to be determined. It is also of interest that aurin tricardid not cause platelet aggregation but potentiated aggregation induced by various agonists, also activated p72 syk . Thus, boxylic acid, which interferes with the interaction between GPIb and vWF, potentiates platelet aggregation induced by it is possible that activation of p72 syk is involved in the generation of an intracellular activation signal and tyrosine phosother agonists. 55 This finding along with those of NNKY5-5 suggest that inhibitors of the interaction between vWF phorylation of the 64-kD protein during NNKY5-5-induced platelet activation, although we have no direct evidence to and GPIb can also be partial activators of platelets. Thus, NNKY5-5 appears to provide a useful tool for investigating support this hypothesis.
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